Drug intelligence / Profile preview

Ordaōs-NonExomics miniPRO (3 novel targets)

Development stage: Preclinical
Lead developer: Ordaos
Modality: Peptides, Recombinant Proteins and Enzymes

Overview

This preclinical-stage program is a collaboration between Ordaōs and NonExomics, focused on the development of miniPRO mini-proteins for the treatment of difficult-to-target rare cancers. The program targets three novel proteins identified by NonExomics from non-conventional protein-coding regions (non-exomic regions). Ordaōs utilizes its proprietary AI-driven Design Engine to generate and rank miniPRO candidates—proteins ranging from 40 to 160 amino acids—that are optimized for stability, manufacturability, and tumor microenvironment penetration.

Other names: miniPROOrdaōs-NonExomics mini-proteins

Beyond the preview

Go deeper on Ordaōs-NonExomics miniPRO (3 novel targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ordaōs-NonExomics miniPRO (3 novel targets).

Explore the full profile